Last $15.00 USD
Change Today +0.40 / 2.74%
Volume 91.2K
FLML On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 10:03 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

flamel technologies-sp adr (FLML) Snapshot

Open
$14.60
Previous Close
$14.44
Day High
$15.20
Day Low
$14.60
52 Week High
06/20/14 - $15.75
52 Week Low
11/11/13 - $5.30
Market Cap
578.7M
Average Volume 10 Days
141.4K
EPS TTM
$-1.00
Shares Outstanding
38.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FLAMEL TECHNOLOGIES-SP ADR (FLML)

Related News

No related news articles were found.

flamel technologies-sp adr (FLML) Related Businessweek News

No Related Businessweek News Found

flamel technologies-sp adr (FLML) Details

Flamel Technologies SA, a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary polymer based technology. The company owns and develops drug delivery platforms, such as Micropump that allows generating and marketing modified and/or controlled release of solid and oral dosage formulations of drugs; and LiquiTime, which develops modified/controlled release of liquid formulations for patients having issues swallowing tablets or capsules. Its drug delivery platforms also comprise Trigger Lock that develops tamper-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, which develops extended/modified release of injectable dosage formulations of drugs. The company’s lead products include Bloxiverz, a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Coreg CR, a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors used for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. It has collaborations with various pharmaceutical and biotechnology companies, including GlaxoSmithKline plc. Flamel Technologies SA was founded in 1990 and is headquartered in Vénissieux, France.

Founded in 1990

flamel technologies-sp adr (FLML) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

flamel technologies-sp adr (FLML) Key Developments

Flamel Technologies SA Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Flamel Technologies SA announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss before income taxes was $20,800,000 against $36,562,000 a year ago. For the six months, the company reported loss before income taxes was $50,235,000 against $46,853,000 a year ago. Net cash used in operating activities was $7,803,000 against $13,462,000 a year ago. Purchases of property and equipment were $515,000 against $715,000 a year ago.

Flamel Receives Communication from FDA to Unapproved Manufacturers of Neostigmine Methylsulfate

Flamel Technologies SA has received communication from the U.S. Food and Drug Administration (FDA) that all manufacturers of unapproved versions of neostigmine methylsulfate have been notified by the FDA to cease manufacturing of the unapproved product as of July 30, 2014. Current inventory in the channel of the unapproved product can continue to be sold. Flamel has not been provided with information on the inventory levels held by these manufacturers.

Flamel Technologies Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Flamel Technologies reported consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $8.1 million, an increase of $2.5 million in revenues compared to the prior year period. Total net interest income was $94,000 in the second quarter of 2014 compared to interest expense of $640,000 in the second quarter of 2013. Net loss was $21.1 million versus net loss of $32.8 million in the year-ago period. Earnings per share (both basic and diluted) was $0.55 in the second quarter of 2014 versus $1.29 in the second quarter of 2013. Adjusted net loss was $4.9 million versus an adjusted net loss of $4.5 million in the second quarter of 2013. Adjusted loss per share (both basic and diluted) was $0.13 in the second quarter of 2014 compared to an adjusted loss per share of $0.18 in the prior year period. Loss from operations was $20.137 million against $34.375 million a year ago. Loss before income taxes was $50.235 million against $46.853 million a year ago. For the six-month, the company reported total revenues were $17.256 million against $10.681 million a year ago. Loss from operations was $44.139 million against $44.226 million a year ago. Loss before income taxes was $20.800 million against $36.562 million a year ago. Net loss was $47.711 million or $1.43 diluted per share against $41.683 million or $1.64 diluted per share a year ago. Adjusted net loss was $6.8 million against adjusted net loss of $10.4 million for the same period a year ago. Adjusted loss per share (both basic and diluted) was $0.20 compared to an adjusted loss per share of $0.41 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLML:US $15.00 USD +0.40

FLML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $13.73 USD -0.16
Durect Corp $1.54 USD -0.01
Onxeo €6.00 EUR +0.03
Veloxis Pharmaceuticals A/S kr1.78 DKK -0.08
XenoPort Inc $4.75 USD -0.09
View Industry Companies
 

Industry Analysis

FLML

Industry Average

Valuation FLML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.1x
Price/Book 9.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLAMEL TECHNOLOGIES-SP ADR, please visit www.flamel-technologies.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.